Despite the advances made in the development of KRAS inhibitors, successful therapies for KRAS mutation-induced cancers, including the direct inhibition of the activity of KRAS and inhibition of downstream KRAS signaling, via the RAF, MEK, and ERK pathways, have not been fully established for several decades [1]. This evidence concerns the gene KRAS and cancer.